Replace repetitive copy-paste work by automatically combining, joining, and importing data directly inside Excel.

GLP-1 medications can alter bowel movements, with constipation and diarrhea being the most common side effects. These drugs slow digestion to help control appetite, which can lead to changes in stool ...

For restaurants and food companies, the increasing adoption of GLP-1 drugs present both an opportunity and a threat to their businesses. About one in every eight U.S. adults is currently taking a ...

Something to look forward to: A resourceful team of modders has set the ambitious goal of transforming the entire Baldur's Gate 1 game into a custom campaign using the Baldur's Gate 3 engine. Powered ...

Kendra Pierre-Louis: For Scientific American’s Science Quickly, I’m Kendra Pierre-Louis, in for Rachel Feltman. In early March the U.S. Food and Drug Administration sent a warning letter to Novo ...

Following a rapid increase in popularity of GLP-1 drugs for diabetes and weight loss, such as semaglutide and tirzepatide, approximately one in eight U.S. adults now take these medications, which also ...

Washington state has beaten California and New York in their race to soak the rich. While California and New York have, respectively, the highest and third-highest state income tax rates, Washington's ...

Although one GLP-1 study made national headlines about the drug class’ potential use in addiction treatment, other research indicates GLP-1s could increase the risk of bone injuries and are less ...

Every bite matters when you start taking a GLP-1. Prioritizing nutrient-dense foods that support your gut and digestive health and maintaining proper hydration can make a real difference in your ...

Nick Blackmer is a librarian, fact-checker, and researcher with more than 20 years of experience in consumer-facing health and wellness content. New research suggests prolonged GLP-1 use may be linked ...

Target-trial emulation in VA EHRs constructed eight parallel new-user trials comparing GLP-1 RA initiators with SGLT-2 inhibitor initiators under two protocols: incident SUDs and SUD-related adverse ...